Chiome Bioscience (4583.T) traded up 2.22 % during a 24 hours period ending at 08:03 AM Central Europe on Tuesday 27th. One Chiome Bioscience stock can currently be bought for about JPY 92 on popular exchanges. Current supply of Chiome Bioscience stocks is 81.1 mn. Chiome Bioscience has a current market capitalization of JPY 7.5 bn and approximately JPY 33.2 mn worth of Chiome Bioscience was traded on exchanges in the last 24 hours. Since last month end, Chiome Bioscience has traded -12.38 % down. Simple moving average of last 200 days is at JPY 93.66. The highest price of past 52 weeks was recorded at JPY 136 on 11/11/2025. 52 weeks low was at JPY 65 on 06/25/2026.

Here is how related stocks have performed in the past 24 hours:

  • Cookpad (2193.T) traded up 0.81 % and now trades at JPY 125. Current market capitalisation for Cookpad is JPY 8.9 bn. Cookpad has a current price to earnings ratio of 7.47.

  • Unicon (407A.T) traded up 0.45 % and now trades at JPY 896. Unicon has a market capitalisation of JPY 8.9 bn. Current price/earnings ratio for Unicon is 8.91.

  • Solekia (9867.T) traded flat 0 % and now trades at JPY 10,250. Current market capitalisation for Solekia is JPY 8.9 bn. Current price/earnings ratio for Solekia is 5.17.

  • Create Medic (5187.T) traded up 0.81 % and now trades at JPY 1,121. Create Medic has a market capitalisation of JPY 8.9 bn. Current price/earnings ratio for Create Medic is 18.05.

  • Yamashita Health Care Holdin (9265.T) traded down -0.14 % and now trades at JPY 3,475. Yamashita Health Care Holdin has a market capitalisation of JPY 8.9 bn. Current price/earnings ratio for Yamashita Health Care Holdin is 15.98.

About Chiome Bioscience

Chiome Bioscience Inc. is a health care company operating in the life sciences tools & services sector with its main operations based in Tokyo, Japan. The company specializes in drug discovery platform technology worldwide, with its proprietary ADLib System monoclonal antibody generating technology being the focus of its drug discovery and development efforts. Through Drug Discovery and Development Business and Drug Discovery Support Business segments, Chiome Bioscience Inc. works to advance various antibody drugs in-house or in collaboration with partners up to late pre-clinical stage, ultimately preparing data packages for IND or early clinical stage in diverse therapeutic areas. The Drug Discovery Support Business segment offers fee-for-service to pharmaceutical and diagnostics companies; and academia, providing support for research works by generating a monoclonal antibody using its proprietary platform, expressing, culturing, and purifying proteins including antigens and antibodies. Chiome Bioscience Inc.’s product pipeline includes LIV-1205, a humanized anti-DLK-1 antibody to treat liver cancer and intractable cancers; LIV-2008/LIV-2008b, a humanized anti-TROP-2 antibody for the treatment of TROP-2; and BMAA, a humanized anti-semphoring 3A antibody for treating semaphorin 3A. The company was founded in 2005 and is currently headquartered in Tokyo, Japan. The website for Chiome Bioscience Inc. is www.chiome.co.jp , and the company’s IPO took place on the Tokyo Stock Exchange in December 2011.